CMV Vaccine Study for Liver Transplant Candidates
Part of Digestive system, Immune system & allergy, Infections clinical trials.
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have never had a CMV infection (tested negative for CMV antibodies).
- You are not infected with HIV.
- You are planning to receive your first liver transplant from a living or deceased donor, expected within 1 to 12 months.
- If you are of childbearing potential, you must agree to use contraception for at least 1 month after the last vaccine dose.
- Your platelet count must be at least 20,000 cells/mm³ within the last 3 months.
- You have not received a CMV vaccine before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
This trial tests a new medicine, Leymovir, against a standard one, Valganciclovir, to prevent a common virus infection (CMV) after a first kidney transplant. It may help you avoid CMV-related illness.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.